Merck targets high-risk military veterans for hepatitis C lessons

Merck has already found success among vets with hep C combo med Zepatier, which pulled in $895 million through the first six months of 2017.

Veterans are three times more likely to have hepatitis C than the general populationand Merck & Co. wants to make sure they know that.

The pharma giant, which makes the hep C-fighting therapy Zepatier, has partnered up with the American Liver Foundation, which will join educational events in Boston, Philadelphia, Phoenix and San Diego to speak with veterans about their risk factors, dole out tips and resources for living with hep C, and provide info about testing and treatment.

The awareness push comes as Merck has been focusing on veterans as a market for Zepatier, which was third to the next-gen hep C market after Gilead Sciences, with its megablockbuster meds, and AbbVie's Viekira Pak. In May of last year, executives at rival AbbVie told investors the New Jersey drugmaker had introduced steeper-than-expected discounts for the U.S. Department of Veterans Affairs, snapping up a good portion of AbbVie’s market share in that segment.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

RELATED: As Merck cans another hepatitis C project, can leader Gilead capitalize?

Those gains helped Zepatier churn out $555 million in 2016 sales, and for the first six months of 2017, that total was already up to $895 million.

Zepatier’s growth is important for Merck, which recently canned a pair of hep C development projects in the face of increasing competition.

“This decision was made based on a review of available phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options available for patients with chronic HCV infection,” the company said in a statement, adding that Merck would instead focus on maximizing Zepatier’s potential.


RELATED: Gilead pushes hep C testing in baby boomers as its blockbusters plummet

Meanwhile, Merck isn’t the first hep C drugmaker to home in on a specific group of high-risk people for its awareness efforts. Earlier this year, Gilead Sciences aimed an educational push at baby boomers, encouraging the 75 million members of that generation1 in 30 of whom has hepatitis C and may not know itto get tested for the virus.

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.